NASDAQ:TRIB - Trinity Biotech Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.78 -0.11 (-3.81 %)
(As of 04/23/2019 04:00 PM ET)
Previous Close$2.89
Today's Range$2.75 - $2.90
52-Week Range$2.13 - $5.25
Volume118,743 shs
Average Volume41,578 shs
Market Capitalization$66.83 million
P/E Ratio21.00
Dividend YieldN/A
Beta1.56
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research industries. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.

Receive TRIB News and Ratings via Email

Sign-up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TRIB
CUSIPN/A
Phone353-1276-9800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$97.04 million
Cash Flow$0.2945 per share
Book Value$1.83 per share

Profitability

Net Income$-22,090,000.00

Miscellaneous

EmployeesN/A
Market Cap$66.83 million
Next Earnings Date5/7/2019 (Estimated)
OptionableOptionable

Trinity Biotech (NASDAQ:TRIB) Frequently Asked Questions

What is Trinity Biotech's stock symbol?

Trinity Biotech trades on the NASDAQ under the ticker symbol "TRIB."

How were Trinity Biotech's earnings last quarter?

Trinity Biotech plc (NASDAQ:TRIB) issued its earnings results on Thursday, March, 7th. The company reported $0.07 EPS for the quarter, beating the Zacks' consensus estimate of $0.04 by $0.03. The business had revenue of $24.52 million for the quarter. Trinity Biotech had a negative net margin of 22.76% and a positive return on equity of 3.91%. View Trinity Biotech's Earnings History.

When is Trinity Biotech's next earnings date?

Trinity Biotech is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Trinity Biotech.

Has Trinity Biotech been receiving favorable news coverage?

Headlines about TRIB stock have trended positive on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Trinity Biotech earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days.

Who are some of Trinity Biotech's key competitors?

What other stocks do shareholders of Trinity Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trinity Biotech investors own include Netflix (NFLX), QUALCOMM (QCOM), Celgene (CELG), Gilead Sciences (GILD), Novavax (NVAX), Supernus Pharmaceuticals (SUPN), Expedia Group (EXPE), Illumina (ILMN), Nightstar Therapeutics (NITE) and Opko Health (OPK).

Who are Trinity Biotech's key executives?

Trinity Biotech's management team includes the folowing people:
  • Mr. Ronan O'Caoimh, Co-Founder, Chairman & CEO (Age 63)
  • Mr. Kevin Tansley, CFO, Company Sec. & Exec. Director (Age 48)
  • Dr. James Walsh, Exec. Director (Age 61)

How do I buy shares of Trinity Biotech?

Shares of TRIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trinity Biotech's stock price today?

One share of TRIB stock can currently be purchased for approximately $2.78.

How big of a company is Trinity Biotech?

Trinity Biotech has a market capitalization of $66.83 million and generates $97.04 million in revenue each year.

What is Trinity Biotech's official website?

The official website for Trinity Biotech is http://www.trinitybiotech.com.

How can I contact Trinity Biotech?

Trinity Biotech's mailing address is IDA BUSINESS PARK BRAY, WICKLOW L2, . The company can be reached via phone at 353-1276-9800 or via email at [email protected]


MarketBeat Community Rating for Trinity Biotech (NASDAQ TRIB)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  147 (Vote Outperform)
Underperform Votes:  202 (Vote Underperform)
Total Votes:  349
MarketBeat's community ratings are surveys of what our community members think about Trinity Biotech and other stocks. Vote "Outperform" if you believe TRIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel